Introduction {#s01}
============

Genetic, pathological, and experimental modeling data all provide strong evidence that numerous neurodegenerative diseases are proteinopathies triggered by the accumulation of proteins within the brain ([@bib21]; [@bib29]). Although there is reasonable consensus that protein aggregation is tightly associated with neurodegeneration, there is limited understanding regarding (1) how protein aggregation impacts neurodegeneration, (2) what events trigger protein aggregation in the absence of mutations or overexpression, and (3) whether therapeutically targeting this aggregation leads to disease modification.

Decades of research into neurodegenerative proteinopathies using in vivo and in vitro models have linked mutations and overexpression of these aggregation-prone proteins to the development of inclusions ([@bib21]; [@bib64]; [@bib29]; [@bib26]). Despite this intensive body of work in the field, mechanistic insights and therapeutic development have been limited by a lack of facile in vitro models that fully recapitulate proteinopathies found in humans. Exciting observations and preclinical development have mostly been conducted in vivo in mammalian models. Specifically, in the case of tau pathology, such as that observed in Alzheimer's disease (AD), robust neurofibrillary tangle (NFT) development and pathology are only observed in transgenic rodent models ([@bib52]; [@bib1]; [@bib9]; [@bib61]). These models restrict throughput and are expensive to maintain and age. Phenotypic variability in transgenic tau mice has been reported ([@bib81]), with gender differences and other confounding variables often cited ([@bib61]; [@bib42]), thereby hindering both preclinical therapeutic studies and studies probing mechanisms regulating tau pathology and tau-induced neurodegeneration. Nonmammalian models have been useful in enabling behavioral screening and the study of tau phosphorylation, but no evidence of true tau inclusion pathology has been observed ([@bib41]; [@bib48]; [@bib7]). Primary neuronal cultures or neuronally differentiated human induced pluripotent stem cell cultures have been used in efforts to create a reliable culture system to recapitulate inclusion pathology reflective of that observed in AD or Parkinson's disease (PD; [@bib13]; [@bib70]). However, none have reproducibly and robustly shown mature neurofibrillary pathologies resembling those in human tauopathies or Lewy body (LB) pathology reminiscent of those found in PD. Further, these systems are not comprised of all the central nervous system (CNS) cell types, which may play a role in disease ([@bib13]; [@bib70]). Indeed, in AD, where a genetic role of microglia has emerged recently ([@bib34]; [@bib76]; [@bib68]), an accessible system that enables the study of all the neuronal and nonneuronal cell types and their interactions in an environment where anatomical planes of connectivity are maintained would be highly useful.

On this basis, we explored the feasibility of combining over a decade of experience in our laboratories optimizing CNS delivery of recombinant adeno-associated viruses (rAAVs) with a three-dimensional intact brain slice culture (BSC) system to see if we could develop more robust ex vivo models of AD and PD inclusion pathologies. These three-dimensional BSCs are functionally and physiologically relevant ([@bib6]; [@bib5]; [@bib19]), can be derived from brain areas involved in the human disease, and are comprised of neuronal and nonneuronal cell types. In addition, BSCs can often predict in vivo findings such as acute treatment of BSCs with small molecule compounds, recapitulating data obtained in in vivo studies ([@bib14]); other similarities and differences between in vivo models and BSCs are reviewed extensively by others ([@bib74]; [@bib39]). We find that rAAVs can be used to efficiently target neurons, astrocytes, microglia, and oligodendrocytes in this system and that expression is sustained long-term in culture. In addition, various brain cell types can be individually or simultaneously targeted in the same cultures, allowing the study of both cell autonomous and nonautonomous effects.

By using rAAVs to express unique combinations of disease-associated microtubule-associated protein tau (*MAPT*) mutations in cis ([@bib73]), we show that BSCs develop an abundance of mature neurofibrillary inclusions (\>1,000 inclusions per BSC) over a period of 7--28 d in vitro (DIV). These inclusions are Thioflavin S--positive, comprised of highly phosphorylated, sarkosyl-insoluble tau, and contain a multitude of tau filaments upon examination by electron microscopy (EM). BSCs transduced with mutant pro-aggregant tau show increased cell death at 60 DIV. We show that these tau-transduced BSCs can be used to screen for compounds that alter tau pathology, bypassing the need for blood--brain barrier penetrant compound, showing the potential of this system to streamline preclinical investigations of tau candidates and rapidly identify the most appropriate pathways to target. We also demonstrate robust inclusion pathology in BSCs transduced with WT and mutant human α-synuclein, providing a second example of a neurodegenerative proteinopathy that can be modeled in this system. Our data exemplify an efficient ex vivo platform to study disease mechanisms associated with pathogenic inclusion formation, as well as a platform to screen for compounds targeting protein aggregation and inclusion formation in relevant CNS cell types.

Results {#s02}
=======

rAAV vectors drive long-term and cell type--specific transgene expression in BSCs {#s03}
---------------------------------------------------------------------------------

To identify appropriate capsid serotypes to transduce BSCs, we evaluated transduction of rAAV2 vectors expressing enhanced GFP (EGFP) pseudotyped with a number of rAAV capsids. BSCs were prepared and transduced at 0 DIV with rAAVs packaged in capsid serotype 1--9 expressing an EGFP transgene under control of the hybrid cytomegalovirus enhancer/chicken β-actin promoter (hCBA). BSCs were maintained in culture until 28 DIV, when slices were fixed and EGFP fluorescence was assessed. BSCs were efficiently transduced by rAAV2 vectors pseudotyped with capsids 1, 2, 6, 8, and 9, inefficiently transduced by capsids 3 and 4, and poorly transduced by capsids 5 and 7 ([Fig. 1 A](#fig1){ref-type="fig"} and Fig. S1).

![**Neurons, astrocytes, oligodendrocytes, and microglia in BSCs can be targeted using different rAAV promoter-capsid combinations. (A)** Organotypic BSCs were prepared and transduced at 0 DIV with rAAVs (1--2 × 10^10^ VGs per well) packaged in capsid serotype 2/1, 2/2, 2/3, 2/4, 2/6, 2/8, and 2/9 to express an EGFP transgene driven by the hCBA promoter. BSCs were maintained in culture until 28 DIV, and then slices were fixed, and fluorescence of EGFP throughout the BSC was imaged. Bar, 100 µm; *n* = 9 slices from *n* = 3 wells. **(B)** BSCs were prepared and transduced at 0 DIV with rAAVs (1--2 × 10^10^ VGs per well) with the hCBA promoter to express EGFP packaged in rAAV2/8, a CamKII promoter to express EGFP packaged in rAAV2/8, a CD68 promoter to express EGFP packaged in rAAV2/6 with three mutations---Y731F/Y705F/T492V (TM6)---an MBP promoter to express EGFP packaged in rAAV2/8, and a GFAP promoter to express EBFP packaged in rAAV2/8. BSCs were maintained in culture until 7, 28, and 90 DIV. Slices were then fixed, and fluorescence of EGFP/EBFP of CNS cells at these time points in the BSCs was imaged. Bar, 25 µm.](JEM_20182184_Fig1){#fig1}

To extend these findings, we evaluated the effectiveness of targeting expression to specific brain cell populations using rAAV2 vectors containing neuronal and nonneuronal promoters pseudotyped with various capsids and expressing various fluorescent proteins ([Fig. 1 B](#fig1){ref-type="fig"}). rAAV2/8 with a hCBA promoter drove EGFP expression in neuronal and nonneuronal cells with rapid and robust expression observed from 7 to 90 DIV. rAAV2/6 with a CamKII promoter restricted expression to neurons, as predicted by in vivo neuronal targeting using the CamKII promoter with rAAVs ([@bib55]). rAAV2/6 with three mutations---Y731F/Y705F/T492V (abbreviated as TM6)---and a cluster of differentiation 68 (CD68) promoter ([@bib65]) selectively targeted EGFP transgene expression to microglia ([Fig. 1 B](#fig1){ref-type="fig"}), with expression again detected from 7 to 90 DIV. To enable accurate quantification of the transduction of microglia, we also prepared BSCs from the CX3CR1-EGFP transgenic mouse line, which enabled visualization of EGFP in microglia ([@bib44]) and transduced these with rAAV2/TM6-CD68-mCherry. We see 40% colocalization between mCherry and EGFP (Fig. S2 B). Counterstaining by immunohistochemistry with a marker for CD68 confirms colocalization between the EGFP and microglial staining (Fig. S2 E). Of particular note, at 7 DIV, microglia are in an amoeboid state, similar to other in vitro cultures of microglia ([@bib71]). This activated state is likely due to the initial trauma following slice generation; however, microglia appear to return to a resting state morphology beyond 7 DIV ([@bib56]). rAAV2/8 with a myelin basic protein (MBP) promoter drove EGFP transgene expression in cells of the oligodendrocyte lineage ([Fig. 1 B](#fig1){ref-type="fig"}); counterstaining with a marker for MBP confirms colocalization between the EGFP and an oligodendrocyte marker (Fig. S2 C). rAAV2/8 with a glial fibrillary acidic protein (GFAP) promoter drove expression of an enhanced blue fluorescent protein (EBFP) transgene to astrocytes in this culture system ([Fig. 1 B](#fig1){ref-type="fig"}), and counterstaining with a marker for GFAP confirms colocalization between the EBFP and the astrocyte marker (Fig. S2 D). Notably, there is no overlap in transgene expression when neuronal, astrocytic, and microglial promoters are used to drive fluorescent protein expression (Fig. S2 A; in this case, the MAP-2 promoter is used as an alternative to CamKII promoter for neuronal expression). These data show that neurons, microglia, oligodendrocytes, and astrocytes can be targeted by rAAVs in BSCs, with expression evident from 7 to ≥90 DIV. These findings are summarized in [Table 1](#tbl1){ref-type="table"}.

###### Summary of targeting neurons, microglia, oligodendrocytes, and astrocytes using rAAVs in BSCs

  BSC cell type      Promoter        Capsid
  ------------------ --------------- ---------------------------------------------------
  Non-specific       hCBA            2/1, 2/2, 2/6, 2/8, 2/9
  Microglia          CD68            2/6 with three mutations, Y731F/Y705F/T492V (TM6)
  Neurons            CamKII, MAP-2   2/6, 2/8
  Oligodendrocytes   MBP             2/8
  Astrocytes         GFAP            2/8

In some studies, we have shown that GFAP promoter--driven expression of BFP in astrocytes and CamKII promoter--driven expression of EGFP in neurons within the rAAV-transduced BSCs can last for at least 9 mo (Fig. S3).

We also investigated whether we could deliver multiple rAAVs to the same BSCs. As shown in Fig. S2 A, rAAV2/TM6-CD68-mCherry, rAAV2/8-MAP-2-YFP, and rAAV2/8-GFAP-BFP applied to BSCs at 0 DIV and fluorescence imaged at 14 DIV show no overlap. This indicates that cell-autonomous and -nonautonomous effects can be studied using different promoter and capsid serotype combinations to deliver genes of interest to the same BSCs. To apply this to a context to understand the biology of human MAPT in these BSCs, we examined transduction of BSCs at 0 DIV with rAAV2/8-GFAP-BFP, rAAV2/8-MAP-2-YFP, and rAAV2/8-hCBA-WT-tau-dsRed and imaged them at 28 DIV ([Fig. 2 A](#fig2){ref-type="fig"}). These images confirm that cells expressing both dsRed and the cells expressing YFP and dsRed enable the study of human tau in astrocytes and neurons, respectively, in a single BSC. In addition, rAAV2/8-hCBA-EGFP and rAAV2/8-hCBA-mApple expressed in the same slice cultures show excellent colocalization ([Fig. 2 B](#fig2){ref-type="fig"}), enabling the study of two genes in the same cells in this system.

![**Multiple CNS cell types can be targeted simultaneously in BSCs or cotransduced using rAAV vectors. (A)** Organotypic BSCs were prepared and transduced at 0 DIV with three rAAVs (1--2 × 10^10^ VGs per well): a MAP-2 promoter to express YFP packaged in rAAV2/8 (green), a hCBA promoter to express human WT tau packaged in rAAV2/8 (red), and a GFAP promoter to express EBFP packaged in rAAV2/8 (blue), fixed at 28 DIV. Then fluorescence throughout the entire BSC was imaged. Bar, 200 µm. **(B)** Organotypic BSCs were prepared and transduced at 0 DIV with two rAAVs: a hCBA promoter to express EGFP packaged in rAAV2/8 (green), and a hCBA promoter to express mApple (red), fixed at 14 DIV. Then fluorescence throughout the entire BSC was imaged to identify colocalization. Bar, 50 µm.](JEM_20182184_Fig2){#fig2}

Progressive and robust neurofibrillary inclusion pathology driven by rAAVs expressing MAPT in BSCs {#s04}
--------------------------------------------------------------------------------------------------

Tau inclusions are a pathological hallmark of the tauopathies including AD, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). The tauopathies are symptomatically and pathologically heterogeneous ([@bib80]; [@bib35]). Tau inclusions are comprised of numerous forms of aggregated, post-translationally modified tau including highly phosphorylated, cleaved, and acetylated species ([@bib35]). Previous BSC models prepared from tau transgenic mice have enabled insight into mechanisms of tau phosphorylation, kinase activation, and physiological and pathological tau release ([@bib20]; [@bib58]; [@bib14],[@bib15]), but robust neurofibrillary inclusions have not been reported.

We recently identified a FTDP-17--associated mutation---S320F ([@bib66])---that is prone to aggregate in an HEK293T cell assay ([@bib73]). In combination with other disease-associated *MAPT* variants, one can generate increasingly more pro-aggregant constructs ([@bib73]). We used rAAV to express these and other 0N4R *MAPT* constructs ([Fig. 3 A](#fig3){ref-type="fig"}) in BSCs in an attempt to elicit neurofibrillary pathology in this model. Initially, BSCs were transduced with rAAV2/8-EGFP, rAAV2/8-WT-htau-EGFP, rAAV2/8-S320F-htau-EGFP, rAAV2/8-P301L/S320F-htau-EGFP, or rAAV2/8-A152T/P301L/S320F-htau-EGFP fusion constructs. Low-speed supernatant (soluble) and sarkosyl-insoluble fractions were prepared ([@bib53]) from the BSC lysates and run on immunoblots. The low-speed supernatant fraction shows overexpression of total tau detected by the total tau antibody 3026 ([@bib72]) and phosphorylated soluble tau at Ser202 (CP13) and Ser396/404 (PHF-1) induced by all htau-EGFP constructs ([Fig. 3 B](#fig3){ref-type="fig"}). Additionally, BSCs expressing tau with the unique combinations of *MAPT* mutations, P301L/S320F or A152T/P301L/A152T, developed an abundance of sarkosyl-insoluble, hyperphosphorylated tau ([Fig. 3 B](#fig3){ref-type="fig"}), a finding not observed in BSCs transduced with EGFP, WT, or S320F tau. Immunohistochemistry of tau phosphorylated at Ser202/Thr205 (AT8) and at Ser396/404 (PHF-1) was performed in order to assess the inclusion pathology ([Fig. 3 C](#fig3){ref-type="fig"}). BSCs from nontransgenic mice have previously been shown to develop some soluble phosphorylated tau in culture ([@bib15]), and this can also be observed in BSCs transduced with EGFP. Both WT and S320F tau cause the accumulation of phosphorylated tau, which is distributed throughout the axons and somatodendritic compartments of neurons. The P301L/S320F and P301L/S320F/A152T constructs, however, drive the accumulation of phosphorylated tau to the somatodendritic compartment, a finding resembling that described for tau inclusions in humans ([@bib32]; [@bib78]).

![**rAAV tau-EGFP fusion protein transduced BSCs develop highly phosphorylated and sarkosyl-insoluble tau inclusions. (A)** Schematic diagram of rAAV human mutant and WT tau constructs under a hCBA promoter used to transduce organotypic BSCs. Slice cultures were prepared and transduced with rAAV2/8-EGFP, rAAV2/8-WT-htau-EGFP, rAAV2/8-S320F-htau-EGFP, rAAV2/8-P301L/S320F-htau-EGFP, or rAAV2/8-A152T/P301L/S320F-htau-EGFP (1--2 × 10^10^ VGs per well) at 0 DIV and then maintained in culture until 28 DIV. **(B)** Transduced slices were sequentially extracted in order to prepare sarkosyl-insoluble tau fractions, and then lysates were immunoblotted for tau phosphorylated at Ser202 (CP13), tau phosphorylated at Ser396/404 (PHF-1), total tau (3026), and β-actin as a loading control. Representative Western blots of tau in the low speed supernatant and sarkosyl-insoluble fraction are shown. *n* = 9. **(C)** Transduced slice cultures were fixed, immunostained for tau phosphorylated at Ser396/Ser404 (PHF-1) and tau phosphorylated at Ser202/Thr205 (AT8), and confocal imaged to identify the location of phosphorylated tau in these sections. Asterisks mark examples of cells showing somatodendritic accumulation of phosphorylated tau. Bar, 25 µm. *n* = 3.](JEM_20182184_Fig3){#fig3}

To further examine tauopathy formation in tau-transduced BSCs and the nature of inclusion pathology, untagged tau constructs, rAAV2/8-WT-htau, rAAV2/8-S320F-htau, rAAV2/8-P301L/S320F-htau, or rAAV2/8-A152T/P301L/S320F-htau ([Fig. 3 A](#fig3){ref-type="fig"}), were delivered to BSCs at 0 DIV, and BSCs were analyzed at 28 DIV. The low-speed supernatant fraction confirms overexpression of total tau (3026) and phosphorylated soluble tau at Ser202 (CP13) and Ser396/404 (PHF-1) in all BSCs transduced with untagged tau constructs ([Fig. 4 A](#fig4){ref-type="fig"}). BSCs expressing untagged P301L/S320F and A152T/P301L/S320F forms of tau accumulate appreciable amounts of sarkosyl-insoluble hyperphosphorylated tau ([Fig. 4 A](#fig4){ref-type="fig"}). The intraneuronal distribution of phosphorylated tau was examined using immunofluorescence. Small amounts of tau phosphorylated at Ser202 (CP13) and Ser396/404 (PHF-1) can be seen in the EGFP control ([Fig. 4 B](#fig4){ref-type="fig"}). Both WT and S320F tau-transduced BSCs show increased tau phosphorylated at Ser202 (CP13) and Ser396/404 (PHF-1) throughout the axons and somatodendritic compartments of neurons ([Fig. 4 B](#fig4){ref-type="fig"}). In contrast, P301L/S320F and P301L/S320F/A152T tau constructs cause the accumulation of phosphorylated tau within the somatodendritic compartment and form inclusion pathology resembling human tau inclusions ([Fig. 4 B](#fig4){ref-type="fig"}). These inclusions in BSCs expressing P301L/S320F and A152T/P301L/S320F tau were Thioflavin S--positive, similar to those seen in human AD ([@bib49]; [Fig. 4 C](#fig4){ref-type="fig"}), whereas Thioflavin S staining was absent from BSCs expressing WT or S320F tau at 28 DIV. Thioflavin S--positive inclusions in the A152T/P301L/S320F tau-transduced BSCs can be seen across the entire slice, with thousands of Thioflavin S--positive inclusions detectable ([Fig. 4 C](#fig4){ref-type="fig"}). rAAV-mediated transduction of tau containing two of the most commonly used FTDP-17 *MAPT* mutations to model disease---P301L and P301S ([@bib40]; [@bib10])---like S320F tau did not show Thioflavin S staining at 28 DIV (Fig. S4). To examine the ultrastructural nature of tau accumulation in A152T/P301L/S320F tau-transduced BSCs, we performed electron-microscopic ultrastructure analyses on BSCs that were transduced at 0 DIV and maintained until 28 DIV. The tau inclusions in these BSCs were comprised predominantly of a mass of orderly straight tau filaments, some with constrictions ([Fig. 4, D and E](#fig4){ref-type="fig"}) as in human AD ([@bib33]; [@bib16]; [@bib60]) and were CP13-positive by Immuno-EM ([Fig. 4 F](#fig4){ref-type="fig"}). Based on this aggregate data, we conclude that the tau inclusions in these BSCs resemble mature neurofibrillary pathology.

![**rAAV tau-transduced organotypic BSCs develop mature neurofibrillary inclusion pathology.** Organotypic BSCs were prepared and transduced with rAAV2/8-EGFP, rAAV2/8-WT-htau, rAAV2/8-S320F-htau, rAAV2/8-P301L/S320F-htau, or rAAV2/8-A152T/P301L/S320F-htau under a hCBA promoter (1--2 × 10^10^ VGs per well) at 0 DIV and then maintained in culture until 28 DIV. **(A)** BSCs were sequentially extracted in order to prepare sarkosyl-insoluble tau fractions, and then lysates were immunoblotted for tau phosphorylated at Ser202 (CP13), tau phosphorylated at Ser396/404 (PHF-1), total tau (3026), and β-actin as a loading control. Representative Western blots of tau in the low-speed supernatant and sarkosyl-insoluble fraction are shown. *n* = 9. **(B)** Transduced slice cultures were fixed at 28 DIV, immunostained for CP13 and PHF-1, and imaged to identify the location of phosphorylated tau in these sections. Asterisks mark examples of cells showing somatodendritic accumulation of phosphorylated tau. Bar, 25 µm. *n* = 3. **(C)** Transduced slice cultures were fixed, stained with 0.0125% Thioflavin S, and confocal imaged to identify any β-sheet structures in these sections. Bar, 25 µm. *n* = 9. A large section spanning an entire BSC transduced with rAAV2/8-A152T/P301L/S320F-htau is also shown. Bar, 100 µm. **(D)** Transduced slices were fixed and examined by EM for the presence of filamentous inclusions. Nucleus, mitochondria (M), Golgi (G), and rough endoplasmic reticulum (RER) are marked. Enlarged section shows bundles of straight tau filaments with some constrictions (red arrows). Bars, 0.2 µm (left); 100 nm (right, enlargement). **(E)** Cross sections show numerous bundles of tau filaments. Bars, 50 nm (top); 100 nm (bottom). **(F)** Immunogold labeling with antibody to tau phosphorylated at Ser202 (CP13) confirms the presence of phosphorylated tau throughout the inclusions (arrows show examples of immunogold-labeled CP13 on tau filaments). Bar, 0.2 µm.](JEM_20182184_Fig4){#fig4}

Initially, we had assessed tau pathology in tau-transduced BSCs at 28 DIV. To assess the timeline of pathology progression in P301L/S320F tau transduced BSCs, BSCs were transduced at 0 DIV and inclusion pathology assessed at 7, 14, 21, and 28 DIV ([Fig. 5 A](#fig5){ref-type="fig"}). A small number of Thioflavin S--positive cells are observed in P301L/S320F tau-transduced BSCs at 7 DIV, and there is a steady increase until 28 DIV. At 28 DIV for WT and S320F tau-transduced BSCs, neither sarkosyl-insoluble tau nor Thioflavin S--positive cells were detectable, despite evidence for high levels of tau expression and increased soluble phosphophorylated tau. However, at 90 DIV, rare Thioflavin S--positive inclusions can be observed in S320F tau-transduced BSCs ([Fig. 5 B](#fig5){ref-type="fig"}), suggesting a progressive development of tau inclusion pathology in this BSC model relating directly to the intrinsic aggregatablity of the expressed tau protein ([@bib73]). We would speculate that expression of P301L or P301S may also drive rare inclusions upon extended culture periods but was not assessed here.

![**Progressive development of NFTs from 7 to 28 DIV in rAAV tau-transduced BSCs. (A)** Organotypic BSCs were prepared and transduced with rAAV2/8-WT-htau or rAAV2/8-P301L/S320F-htau (1--2 × 10^10^ VGs per well) at 0 DIV and then maintained in culture until 7, 14, 21, or 28 DIV. Transduced slice cultures were fixed, stained with 0.0125% Thioflavin S, and confocal imaged to identify any β-sheet structures in these sections. Bar, 100 µm. *n* = 3. **(B)** BSCs were prepared and transduced with rAAV2/8-WT-htau, rAAV2/8-S320F-htau, or rAAV2/8-P301L/S320F-htau at 0 DIV and then maintained in culture until 90 DIV. Transduced slice cultures were fixed, stained with 0.0125% Thioflavin S, and confocal imaged to identify any β-sheet structures in these sections. Bar, 50 µm. *n* = 3.](JEM_20182184_Fig5){#fig5}

We also explored whether tau expression targeted to neurons would drive pathology in this model. BSCs were transduced with WT and mutant rAAV tau constructs driven by a CamKII promoter ([Fig. 6 A](#fig6){ref-type="fig"}). Numerous Thioflavin S--positive inclusions can be observed with CamKII driven expression of mutant tau in these BSCs ([Fig. 6 B](#fig6){ref-type="fig"}), albeit to a lesser extent than hCBA-driven mutant tau, allowing the observation and understanding of tau inclusions selectively driven to neurons in BSCs.

![**Neuronal driven expression of tau to BSCs drives Thioflavin S--positive tau inclusions. (A)** Schematic diagram of rAAV human mutant and WT tau constructs used to transduce organotypic BSCs to neurons only with a CamKII promoter. **(B)** Slice cultures were prepared and transduced with rAAV2/8-CamKII-WT-htau, rAAV2/8-CamKII-P301L/S320F-htau, or rAAV2/8-CamKII-A152T/P301L/S320F-htau (1--2 × 10^10^ VGs per well) at 0 DIV and then maintained in culture until 28 DIV. Transduced slice cultures were fixed, stained with 0.0125% Thioflavin S, and imaged to identify any β-sheet structures in these sections. DAPI is also shown to mark cell nuclei. Bar, 50 µm. *n* = 3.](JEM_20182184_Fig6){#fig6}

Robust neurofibrillary pathology by transduction of MAPT drives neurodegeneration in BSCs {#s05}
-----------------------------------------------------------------------------------------

As burden of tau inclusion pathology correlates with neuronal loss in AD ([@bib31]; [@bib4]), we examined any changes in cell death associated with tau transduction in BSCs. At 7, 14, 21, 28, and 60 DIV, slice cultures were incubated with ethidium homodimer-1 (EthD-1), and uptake by dead cells was imaged ([Fig. 7 A](#fig7){ref-type="fig"}) and quantified ([Fig. 7 B](#fig7){ref-type="fig"}). At 7 DIV, EthD-1 uptake was increased in transduced and nontransduced BSCs as previously reported ([@bib56]). This initial cell death reduced to a background level by 14 DIV, but by 60 DIV, cell death is significantly increased in BSCs transduced with A152T/P301L/S320F tau (P = 0.02) coincident with abundant tau inclusions. This suggests that at this time point, tau-induced neurodegeneration begins to be recapitulated in this model. In BSCs, the increased cell death is associated with an increased propensity of tau aggregation and with additive *MAPT* mutations. It is also important to note that at all of the time points in culture examined, there is no difference in cell death between the EGFP-transduced control and BSCs that have not been transduced.

![**Increased cell death follows mature neurofibrillary inclusion formations in tau-transduced BSCs. (A)** Representative images of EthD-1 uptake (red fluorescence) in BSCs transduced with rAAV2/8-EGFP, rAAV2/8-WT-htau, or rAAV2/8-A152T/P301L/S320F-htau (1--2 × 10^10^ VGs per well) and imaged at 7, 28, and 60 DIV. Bar, 400 µm. **(B)** Bar chart shows numbers of EthD-1--positive (red) cells per mm^2^ in rAAV2/8-EGFP, rAAV2/8-WT-htau, rAAV2/8-S320F-htau, rAAV2/8-P301L/S320F-htau, rAAV2/8-A152T/P301L/S320F-htau, or no rAAV-transduced BSCs at 7, 14, 21, 28, and 60 DIV. Data are mean ± SEM. \*, P \< 0.05. *n* = 6--12.](JEM_20182184_Fig7){#fig7}

Compounds that reduce tau aggregation can be screened in tau-transduced BSCs {#s06}
----------------------------------------------------------------------------

Tau is a well-established target in AD and other tauopathies ([@bib30]; [@bib38]; [@bib45]). Tau therapeutic candidates have been chiefly screened in vivo in transgenic tau mouse models, but this is expensive and laborious, and requires large numbers of aged mice in order to assess effects on tau aggregation and burden. BSC models prepared from tau transgenic mice have previously been used to assess acute effects of compounds on tau phosphorylation ([@bib14]), but no chronic treatment studies have been reported. To assess whether compounds can be administered in a chronic manner in BSCs to modulate tau aggregation, four GSK-3β inhibitors (SB415286, AZD1080, TWS119, and Tideglusib) were applied at 0.1 µM or 1 µM from 14 to 28 DIV in P301L/S320F tau-transduced BSCs. GSK-3β phosphorylates tau and has been implicated as a therapeutic target in tauopathies ([@bib37]; [@bib51]; [@bib77]). At 28 DIV, one of these four GSK3β inhibitors, 1 µM AZD1080 ([@bib23]), showed a significant reduction in PHF-1--positive phosphorylated soluble (P = 0.0031) and sarkosyl-insoluble (P = 0.0001) tau in BSCs ([Fig. 8, A and B](#fig8){ref-type="fig"}) and a reduction in Thioflavin S--positive inclusions ([Fig. 8 C](#fig8){ref-type="fig"}). These data highlight the utility of these tauopathy BSCs for cost-effective preclinical efficacy studies.

![**Tauopathy BSCs can be used for testing tau-targeting therapeutics. (A)** Representative Western blots of lysates from organotypic BSCs transduced at DIV 0 with rAAV2/8-P301L/S320F-htau (1--2 × 10^10^ VGs per well) and then treated from 14 to 28 DIV with 0.1 µM or 1 µM GSK-3β inhibitors. Half maximal inhibitory concentrations (IC50s) for GSK-3β for each compound are listed in parentheses as follows: SB415286 (78 nM), AZD1080 (324 nM), TWS119 (30 nM), and Tideglusib (60 nM). Blots were probed with antibodies against total tau (both nonphosphorylated and phosphorylated; 3026) and PHF-1 (phospho-Ser396/404). Blots were also probed with an antibody against β-actin as a loading control. **(B)** Bar charts show amounts of phospho-tau as a proportion of total tau in low speed supernatant and sarkosyl-insoluble samples after treatment with 0.1 µM or 1 µM GSK-3β inhibitors or DMSO (control). *n* = 3--6. \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001. Data are mean ± SEM and are shown as fold change from DMSO (control). **(C)** Transduced and treated slice cultures were fixed, stained with 0.0125% Thioflavin S, and imaged to identify any β-sheet structures in these sections. DAPI is also shown to mark cell nuclei. Bar, 50 µm. *n* = 6.](JEM_20182184_Fig8){#fig8}

Robust LB pathology can also be driven by rAAVs expressing α-synuclein in BSCs {#s07}
------------------------------------------------------------------------------

PD is the most common motor neurodegenerative disease ([@bib63]). PD is characterized by the presence of α-synuclein inclusions, which are found in PD and other α-synucleinopathies including LB dementia and multiple system atrophy ([@bib46]; [@bib18]). These inclusions are comprised of α-synuclein phosphorylated at Ser129, and this is predominantly used as a marker of α-synuclein inclusions ([@bib22]; [@bib2]). To assess whether we could also drive α-synucleinopathy and the formation of LBs in BSCs, we developed both YFP-fused and untagged WT and A53T *SNCA* rAAV constructs ([Fig. 9 A](#fig9){ref-type="fig"}). BSCs were transduced with WT or A53T human α-synuclein tagged with YFP at 0 DIV, and then BSCs were lysed, and insoluble and soluble α-synuclein was extracted from the BSCs at 28 DIV, as previously described ([@bib67]). These fractions were then immunoblotted for total and pSer129 α-synuclein ([Fig. 9 B](#fig9){ref-type="fig"}). Insoluble and pSer129 α-synuclein accumulated in BSCs transduced with both WT and A53T α-synuclein. BSCs were also fixed at 28 DIV, and immunohistochemistry for pSer129 α-synuclein was performed to assess the distribution of α-synuclein in these transduced BSCs ([Fig. 9 C](#fig9){ref-type="fig"}). The α-synuclein inclusions in both WT- and A53T-transduced BSCs show LB-like inclusions with some Lewy neurites, recapitulating what is seen in human α-synucleinopathies ([@bib46]). The presence of these pSer129 α-synuclein inclusions was also confirmed by immunohistochemistry in BSCs transduced with untagged WT and A53T α-synuclein ([Fig. 9 D](#fig9){ref-type="fig"}), and LBs and Lewy neurites like those found in human α-synucleinopathies ([@bib69]) are observed in these BSCs. Furthermore, when examining rAAV2/8-WT--α-synuclein transduced BSCs by immunogold EM, labeling with an antibody to non-amyloid-β component of plaques (NACP)/α-synuclein confirms the presence of α-synuclein fibrils by 28 DIV ([Fig. 9 E](#fig9){ref-type="fig"}). In these experiments, α-synuclein inclusion pathology was induced using rAAVs from a microscale production of rAAV, avoiding costly purification of the virus (see Materials and methods). To confirm this was not an artifact of using secreted "microscale" rAAVs, BSCs were prepared and transduced with purified rAAVs to express YFP, WT human α-synuclein, or A53T human α-synuclein at 0 DIV and maintained until 28 DIV. BSCs were lysed, and insoluble and soluble α-synuclein was extracted from the BSCs at 28 DIV as performed for "microscale" rAAV-transduced BSCs. These fractions were then immunoblotted and probed for total and pSer129 α-synuclein ([Fig. 9 F](#fig9){ref-type="fig"}). Insoluble and pSer129 α-synuclein accumulated in BSCs transduced with purified rAAVs to express WT and A53T α-synuclein. BSCs were also fixed at 28 DIV, and immunohistochemistry for pSer129 α-synuclein was performed to assess the distribution of α-synuclein in these transduced BSCs ([Fig. 9 G](#fig9){ref-type="fig"}). BSCs transduced with WT or A53T purified or microscale rAAVs show LB-like inclusions and also highlight that the more cost-effective microscale rAAV production method can even further increase the accessibility of this system to model proteinopathies.

![**rAAV α-synuclein-transduced organotypic BSCs develop insoluble α-synuclein inclusions reminiscent of LBs. (A)** Schematic diagram of rAAV human mutant and WT α-synuclein constructs used to transduce organotypic BSCs. BSCs were prepared and transduced with rAAV2/8-YFP, rAAV2/8-h-WT-α-synuclein-YFP, rAAV2/8-h-A53T-α-synuclein-YFP, rAAV2/8-h-WT-α-synuclein, or rAAV2/8-h-A53T-α-synuclein prepared using a microscale method of rAAV preparation at 0 DIV and then maintained in culture until 28 DIV. **(B)** Transduced slices were sequentially extracted in order to prepare soluble and insoluble fractions, and then lysates were immunoblotted for total α-synuclein (SNL-4), phospho-Ser129 α-synuclein (81A), and β-actin as a loading control. Representative Western blots of insoluble and soluble fractions are shown. *n* = 9. **(C and D)** Transduced slice cultures were fixed, immunostained for phospho-Ser129 α-synuclein (EP1536Y), and confocal imaged to identify the location of phosphorylated α-synuclein in these sections. DAPI is also shown to mark cell nuclei. Asterisks mark examples of cells showing accumulation of phosphorylated α-synuclein and a LB-like appearance. Bar, 25 µm. *n* = 3. **(E)** rAAV2/8-h-WT-α-synuclein transduced slices were fixed and examined by immuno-EM for the presence of filamentous inclusions. Immunogold labeling with antibody to NACP98 confirms the presence of α-synuclein in inclusions (red arrows show examples of immunogold-labeled NACP98 on filaments). Bar, 0.2 µm. BSCs were also prepared and transduced with rAAV2/8-YFP, rAAV2/8-h-WT-α-synuclein, or rAAV2/8-h-A53T-α-synuclein prepared using the traditional purified method of rAAV preparation at 0 DIV and then maintained in culture until 28 DIV. **(F)** Transduced slices were sequentially extracted in order to prepare soluble and insoluble fractions, and then lysates were immunoblotted for total α-synuclein (SNL-4), phospho-Ser129 α-synuclein (81A), and β-actin as a loading control. Representative Western blots of insoluble and soluble fractions are shown. *n* = 3. **(G)** Transduced slice cultures were fixed, immunostained for phospho-Ser129 α-synuclein (EP1536Y), and confocal imaged to identify the location of phosphorylated α-synuclein in these sections. DAPI is also shown to mark cell nuclei. Bar, 20 µm. N.D., not done.](JEM_20182184_Fig9){#fig9}

Discussion {#s08}
==========

Determining mechanisms underpinning proteinopathies including tauopathies and synucleinopathies and developing therapeutics for these diseases have posed an experimental challenge on the basis that ex vivo models recapitulating robust and bona fide inclusion pathology and any associated neurotoxicity do not exist. Here we have experimentally addressed this unmet need and developed models of both tauopathy and α-synucleinopathy. BSCs transduced with rAAV vectors encoding mutant tau progressively develop mature neurofibrillary tau pathology. Over a thousand tau inclusions can reproducibly develop in a single BSC, and the tau inclusion pathologies are characterized by highly phosphorylated, filamentous, sarkosyl-insoluble tau with a β-sheet structure; in other words, they are bona fide mature neurofibrillary tau inclusions by all standard measures ([@bib36]; [@bib59]; [@bib35]). BSCs transduced with a single *MAPT* mutation do develop sparse inclusions by 3 mo, thus providing a panel of tools to analyze varying degrees of tau pathology with differing temporal progression due to the intrinsic aggregatability of the encoded tau protein. Further, restricting tau expression to neurons using a CamKII promoter provides proof of concept that we can drive tau pathology in specific cell types. Coupled with data showing our ability to target expression using various promoter capsid combinations, such data portend the ability to probe how inclusion pathology alters cellular function in each of the major CNS cell types and also examine cell-autonomous and noncell autonomous mechanisms of action. Of note, by 3 mo in vitro, BSCs transduced with WT *MAPT* do not show inclusion pathology but do develop high levels of phosphorylated tau. As with in vivo models expressing WT human tau ([@bib32]; [@bib8]; [@bib3]), development of inclusion pathology may require further time in culture in this system or may require other triggers to transition to its aggregated state, all of which remain open avenues to explore in this system.

Despite intensive study, a detailed mechanistic understanding of how neurofibrillary tau inclusion formation contributes to cellular dysfunction and cell death remains enigmatic, partly due to the absence of suitable models to study. In AD, the burden of tau inclusion pathology correlates with neuronal loss ([@bib31]; [@bib4]). However, NFTs appear to exist in living neurons for decades in the human brain ([@bib9]), and NFT-bearing neurons remain functional in mouse models for considerable periods of time ([@bib50]). In the BSC tauopathy model, we do not see increased cell death at the time during which massive neurofibrillary inclusions are developing. However, we note increased cell death 1 mo later that appears to be associated with the inherent aggregability of the transduced tau.

One of the challenges in the tau field is that a large number of mutations have been linked to human tauopathies, but only a much smaller number of these variants have been investigated with respect to their effects on tau pathology in relevant model systems. As highlighted by our recent study ([@bib73]), it appears that these tau mutants have different rates of intrinsic aggregation as well as marked differences in their ability to aggregate following seeding. The rAAV-transduced BSCs will be an excellent tool to evaluate aggregate formation of additional tau variants in relevant CNS cell types as well as effects on cellular function. Although the simplistic explanation is that A152T in cis with other mutants makes a more pro-aggregant tau, we cannot firmly conclude that this is the reason that the A152T/P301L/S320F tau shows the most abundant pathology and toxicity. Expression of the A152T variant in model systems has previously been linked to a variety of effects in addition to increased NFT formation, including neurotoxicity, enhanced neuronal excitotoxicity, neuroinflammation, altered tau phosphorylation, and tau missorting ([@bib17]; [@bib57]; [@bib62]; [@bib75]).

Despite intense interest in tau as a therapeutic target for nearly two decades, only a small number of tau-targeting therapeutics have advanced to clinical trials, again due to the slow pipeline with an absence of suitable in vitro models that currently exist ([@bib30]; [@bib28]). Few small molecules targeting tau remain in the clinical development pipeline, while the majority of clinical programs are now using active and passive immunotherapies to target tau. Our data evaluating select GSK-3β inhibitors show that BSCs can be used as a preclinical tool to gain confidence in both target engagement and mechanism of action of a tau-targeting therapeutic. Indeed, these studies yielded rather provocative results showing that only one of several GSK-3β inhibitors reduced tau aggregation in a model that recapitulates the three-dimensional architecture of the CNS. Effects on inclusion pathology can be monitored in the BSCs, and effects on tau-induced neurodegeneration could be evaluated. Although a large-scale screen of thousands of agents would not likely be practical in this system, unless highly automated, targeted screens of tens to hundreds of agents are certainly feasible.

Similarly, we extend our findings to show robust inclusion pathology in slices transduced with WT and mutant α-synuclein, providing a second example of a proteinopathy that can be modeled by using rAAVs and BSCs. By 28 DIV*,* BSCs transduced with WT and mutant α-synuclein develop inclusions that contain phosphorylated, insoluble α-synuclein which morphologically recapitulate LBs and show some Lewy neurites like those found in human α-synucleinopathies ([@bib69]; [@bib46]). Again, these provide a rapid in vitro model to study α-synucleinopathies and mechanistically understand or therapeutically target this inclusion pathology. Of importance, this LB pathology was elicited in BSCs transduced from microscale production of the rAAV vectors. More generally, microscale production enables rAAV vectors to be rapidly and cost-effectively prepared at scales suitable for transduction of multiple BSCs at minimal cost, and also enables efficient generation of multiple vectors without the need for a large-scale standard vector preparation. Notably, many proteins linked to CNS proteinopathies fit within the packing limits of rAAV vectors, and in many cases, rAAV-mediated expression and subsequent inclusion pathology in the brain has been documented ([@bib79]; [@bib11]). Thus, it is highly likely that rAAV-mediated expression of proteins linked to other neurodegenerative disorders within BSCs can be developed.

The versatility of rAAV-mediated transgene expression in the BSC system enables targeting of select CNS cell types, either individually or at the same time, and highlights its applicability not only for study of neurodegenerative diseases but also for the study of the physiology of the CNS and other brain diseases. Various rAAV capsid serotypes can be used to effectively transduce BSCs, and these capsids in combination with several neuronal and nonneuronal cell type promoters enable the selective targeting of the major CNS cell types in slice cultures. In all cases, expression is maintained for ≥3 mo in culture, and we have noted neuronal expression even at 9 mo in vitro. Of importance, we also observe that microglia in this system show morphologies of quiescent in vivo--like adult microglia after 1 mo in vitro, enabling the study of microglia in physiology and disease in this system.

Overall, this work highlights this rAAV and BSC "toolkit" as a platform to study neurodegenerative disease mechanisms associated with pathogenic inclusion formation in a rapid, scalable manner. Given the sustained expression and flexibility of this system with the major CNS cell types in an anatomically connected milieu, their roles in physiology and pathology can be studied. This toolkit can also be leveraged to screen for compounds targeting protein aggregation and inclusion formation while remaining time-, resource-, and cost-effective.

Materials and methods {#s09}
=====================

rAAV preparation {#s10}
----------------

rAAV 2/1, 2/2, 2/3, 2/4, 2/5, 2/6, 2/7, 2/8, and 2/9 expressing EGFP; rAAV2/1 expressing 0N4R human tau, htau-WT, htau-S320F, htau-P301L, htau-P301S, and htau-P301L/S320F; and rAAV2/8 expressing htau-WT, htau-S320F, htau-P301L/S320F, htau-A152T/P301L/S320F, htau-WT-EGFP, htau-EGFP, htau-P301L/S320F-EGFP, htau-A152T/P301L/S320F-EGFP, YFP, WT-hα-synuclein, and A53T-hα-synuclein, under the control of the hCBA promoter, were generated as described previously ([@bib12]; [@bib11]; [@bib65]). rAAV2/6 with three mutations---Y731F/Y705F/T492V (abbreviated as TM6; [@bib65])---expressing EGFP or mCherry driven by a CD68 promoter, rAAV2/6 expressing EGFP, htau-WT, htau-P301L/S320F, or htau-A152T/P301L/S320F driven by a CamKII promoter ([@bib55]) or YFP driven by a MAP-2 promoter, rAAV2/8 expressing EGFP driven by an MBP promoter, or EBFP driven by a GFAP promoter were also generated as previously described ([@bib12]; [@bib11]; [@bib65]). rAAVs were applied to BSCs by adding rAAVs into the culture medium on the first day of culture (0 DIV) at 1--2 × 10^10^ viral genomes (VGs) per well containing three BSCs.

Microscale preparation of rAAV {#s11}
------------------------------

rAAV 2/8 expressing YFP, WT-hα-synuclein, A53T-hα-synuclein, WT-hα-synuclein-YFP, and A53T-hα-synuclein-YFP under the control of the hCBA promoter was prepared as microscale rAAVs. HEK293T cells (ATCC) were maintained as recommended in DMEM (Lonza Group) with 10% (vol/vol) FBS (Thermo Fisher Scientific), 2 mM [l]{.smallcaps}-glutamine, and 1% (vol/vol) penicillin/streptomycin (Thermo Fisher Scientific). HEK293T cells were plated in 2 ml media in 6-well plates 24 h before transfection of transgene plasmid with rAAV2/8 (pDP8.ape; Plasmid Factory GmbH & Co. KG) using Polyethylenimine Linear (Polysciences) at 60--80% confluency. The microscale virus was harvested 72 h after transfection by centrifuging the media at 500 *g* for 5 min and collecting the supernatant. Media containing secreted rAAVs were then applied to BSCs by rAAVs into the culture medium on the first day of culture (0 DIV) at 1--2 × 10^10^ VGs per well containing three BSCs.

Organotypic BSC {#s12}
---------------

All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Florida. Organotypic BSCs were prepared from postnatal day 8--9 B6/C3H mice (Envigo) or CX3CR1-GFP transgenic mice ([@bib44]; 005582; The Jackson Laboratory) as previously described ([@bib14]). In brief, pups were cryoanesthetized and decapitated, and the brains removed and dissected to retain the cortex, hippocampus, and connecting regions in each hemi-brain in sterile filtered ice-cold dissection buffer (HBSS, calcium, magnesium, no phenol red \[Thermo Fisher Scientific\], 2 mM ascorbic acid \[Sigma-Aldrich\], 39.4 µM ATP \[Sigma-Aldrich\], and 1% (vol/vol) penicillin/streptomycin \[Thermo Fisher Scientific\]). The hemi-brain was placed on filter paper, and 350-µm coronal slices were cut using a McIllwain tissue chopper (Mickle Laboratory Engineering Co. Ltd.). Slices were collected and plated randomly to contain three slices per semi-porous membrane insert (0.4 µm pore diameter; Millipore; Thermo Fisher Scientific) in 6-well sterile culture plates. Slices from different parts of the brain are therefore distributed randomly across wells of each plate. Slices were maintained at 37°C and 5% CO~2~ in sterile-filtered culture medium (basal medium eagle \[Thermo Fisher Scientific\], 26.6 mM Hepes \[pH 7.1; Thermo Fisher Scientific\], 511 µM ascorbic acid, 1% \[vol/vol\] GlutaMAX \[Thermo Fisher Scientific\], 0.033% \[vol/vol\] insulin \[Sigma-Aldrich\], 1% \[vol/vol\] penicillin/streptomycin \[Thermo Fisher Scientific\], and 25% \[vol/vol\] heat-inactivated horse serum \[Sigma-Aldrich\]). Culture medium was changed every 3--4 d. rAAVs were applied directly into the culture medium on the first day of culture (0 DIV) at 1--2 × 10^10^ genome particles of rAAV per well containing three BSCs.

Treatment of organotypic slice cultures {#s13}
---------------------------------------

Slice cultures were treated with GSK-3β inhibitors from the DiscoveryProbe Kinase Inhibitor Library (ApeXBio) reconstituted in DMSO (Sigma-Aldrich). GSK-3β inhibitors were added at 14, 18, 21, and 25 DIV during media changes to a final concentration of 0.1 or 1 µM of GSK-3β inhibitors in a final concentration of 0.1% DMSO in the media. 0.1% DMSO was used as the control.

Sarkosyl extraction of BSC lysates {#s14}
----------------------------------

Slice cultures for assessment of insoluble tau from three wells (nine slices in total) were harvested into ice-cold PBS and presented as *n* = 1. Slices were washed in PBS and then pelleted, and sarkosyl extractions were performed as previously described ([@bib53]). BSCs were homogenized in Tris-buffered saline (TBS; 50 mM Tris, 274 mM NaCl, and 5 mM KCl, pH 8) containing a protease/phosphatase cocktail (Roche) and centrifuged at 27,000 *g* for 20 min at 4°C. The supernatant (S1) was kept and run on immunoblots as the low-speed supernatant. The pellet (P1) was homogenized in Tris-sucrose buffer (10 mM Tris, pH 7.4, 0.8 M NaCl, and 10% sucrose) and similarly centrifuged. The supernatant (S2) was incubated in 1% sarkosyl for 60 min at 37°C and was centrifuged at 150,000 *g* for 30 min at 4°C. The pellet (P3) was resuspended in Tris-EDTA buffer (10 mM Tris, pH 8, and 1 mM EDTA) and run on immunoblots as the sarkosyl-insoluble fraction.

Triton X-100 extraction of BSC lysates {#s15}
--------------------------------------

Slice cultures for assessment of insoluble α-synuclein from three wells (nine slices in total) were harvested into ice-cold PBS and presented as *n* = 1. Slice cultures were washed and pelleted, and extraction was performed as previously described for primary neuroglia ([@bib67]). Slices were lysed in 1% Triton X-100 TBS (50 mM Tris and 150 mM NaCl, pH 7.4) with protease and phosphatase inhibitors. Lysates were then centrifuged at 100,000 *g* for 20 min at 4°C. Supernatants were removed (Triton-soluble fraction), and the pellet was washed with the TBS buffer and centrifuged at 100,000 *g* for 20 min at 4°C. The pellet was then resuspended in 2% SDS, sonicated, and heated to 100°C for 10 min (Triton-insoluble fraction). Protein concentrations were determined by bicinchoninic acid assay (Thermo Fisher Scientific) before equal amounts of protein were resolved by immunoblotting.

Antibodies {#s16}
----------

The following antibodies were used for immunoblotting and/or immunohistochemistry. A rabbit polyclonal antibody 3026 raised against full-length recombinant 0N3R human tau ([@bib72]) and AT8 (Thermo Fisher Scientific) mouse monoclonal antibody to tau phosphorylated at Ser202 and Thr 205 ([@bib25]) were used. The following mouse monoclonal tau antibodies were provided by Peter Davies (Feinstein Institute for Medical Research, Manhasset, NY): CP13 (tau phosphorylated at Ser202) and PHF-1 (tau phosphorylated at Ser396 and Ser404; [@bib43]). SNL-4, a rabbit polyclonal antibody raised against amino acid sequence 2--12 of human α-synuclein ([@bib24]); 81A, a mouse monoclonal antibody specific for α-synuclein phosphorylated at Ser129; and a rabbit monoclonal antibody specific for α-synuclein phosphorylated at Ser129 (EP1536Y; Abcam) were used. Rabbit polyclonal antibodies to GSK-3β phosphorylated at Ser9 (Cell Signaling Technology) and total GSK-3β (Cell Signaling Technology), mouse monoclonal antibodies to β-actin (Sigma-Aldrich), MAP-2 (Millipore), and GFAP (Cell Signaling Technology) and rat monoclonal antibodies to MBP (Bio-Rad Laboratories) and to CD68 (BioLegend) were also used.

SDS-PAGE and immunoblotting {#s17}
---------------------------

5--20 µg protein was separated on 4--12% or 10% (wt/vol) SDS-PAGE gels (Bio-Rad) and electrophoretically transferred to polyvinylidene difluoride membranes, as described previously ([@bib53]). Membranes were blocked in 0.5% casein for 1 h and then incubated with primary antibodies overnight at 4°C, washed three times with TBS before incubation with fluorophore-conjugated Alexa Fluor 680 anti-mouse IgG (Thermo Fisher Scientific) or IRDye 800 goat anti-rabbit IgG (Li-Cor Biosciences) secondary antibodies, and washed three times with TBS. Protein bands were detected and quantified using the multiplex Li-Cor Odyssey Infrared Imaging system (Li-Cor Biosciences).

Immunohistochemistry {#s18}
--------------------

Organotypic BSCs were washed in PBS and then fixed on their inserts in 4% paraformaldehyde for 1 h and stained according to [@bib27]. Individual slice cultures (*n* = 1) were cut out from their membranes after fixation and then treated as free-floating sections for the following steps. Slice cultures were permeabilized for 18 h in 0.5% Triton X-100 at 4°C and then blocked in 20% BSA (Sigma-Aldrich) for 4 h at room temperature (RT). Slice cultures were then incubated with appropriate primary antibodies overnight at 4°C in 5% BSA, washed, and then incubated with fluorophore-coupled secondary antibodies for 4 h at RT. Slice cultures were washed a final time before mounting on slides with Fluoromount-G with DAPI (Southern Biotech) and then imaged.

Thioflavin S staining {#s19}
---------------------

Organotypic BSCs were washed in PBS, fixed on their inserts with 4% paraformaldehyde for 1 h, and then stained with 0.0125% Thioflavin S as described in [@bib73]. In brief, a stock solution of 1% Thioflavin S (Sigma-Aldrich) in 50% EtOH in PBS was filtered through a 0.2-µm filter. Individual slices (*n* = 1) were cut from their membranes and autofluorescence reagent (Millipore) was applied for 5 min, and then slices were washed in 40% ethanol (EtOH). BSCs were incubated with 0.0125% Thioflavin S in 50% EtOH in PBS for 3 min in the dark, followed by 50% EtOH and PBS washes. BSCs were then mounted on slides with Fluoromount-G with DAPI (Southern Biotech) and then imaged to identify any amyloidogenic β-sheet structures in these sections.

Imaging of slice cultures {#s20}
-------------------------

Images of slice cultures were captured using a Nikon A1RMPsi-STORM4.0 multiphoton/super resolution imaging system (Nikon Instruments) on the laser-scanning confocal mode or using a Keyence BZ-X700 all-in-one fluorescence microscope (Keyence Corp. of America) using the optical sectioning mode. Z-stacks were captured over 20 µm at recommended step-sizes and projected onto a full focus image using the BZ-analyzer or Nikon Elements software.

EthD-1 dead cell uptake assay {#s21}
-----------------------------

Cytotoxicity was assessed by measuring EthD-1 uptake. EthD-1 was prepared according to the manufacturer's instructions (LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells; Thermo Fisher Scientific). Culture medium was aspirated from slice cultures, and wells were washed in prewarmed PBS. Slice cultures were then incubated with EthD-1 in PBS for 15 min and then imaged. Three images of each slice were captured blindly from predetermined regions using a 10× objective lens, positive cells were counted using the analyze particles feature on ImageJ (Version 1.51k; National Institutes of Health), and the mean number of positive cells calculated from the three images captured.

EM {#s22}
--

BSCs were fixed on the culture insert with 2.5% glutaraldehyde-2% paraformaldehyde in PBS at 4°C overnight and washed in PBS. EM was performed as previously described ([@bib54]). Slices were scraped into PBS and centrifuged for 1 min at 16,000 *g* to form tissue pellets and were transferred to glass vials and fixed in aqueous osmium tetroxide (2%) for 1 h at RT, followed by 2% uranyl acetate in 50% EtOH for 30 min at RT. Tissues were then dehydrated in a series of EtOHs and propylene oxide, infiltrated and embedded in epon 812 (Polysciences). Thin sections were stained with uranyl acetate and lead citrate, examined with a Philips 208s electron microscope fitted with a Gatan 831 Orius digital camera. Digital images were processed with Adobe Photoshop software.

Post-embedding immunogold EM {#s23}
----------------------------

BSCs were fixed in 4% paraformaldehyde in PBS at 4°C overnight, and collected into pellets as for regular EM. Pellets were transferred to glass vials dehydrated in 50, 70, 80, and 90% EtOH for 10 min at RT, infiltrated, and embedded in LR White resin (medium grade; Polysciences). They were polymerized in a vacuum oven at 50°C for 2 d. Thin sections were collected on Formvar-coated grids and were incubated with antibody CP13 or NACP-98 ([@bib47]) overnight at 4°C, followed by goat anti-mouse IgG conjugated with 18 nm colloidal gold particles (Jackson ImmunoResearch Laboratories) for 30 min at RT. The sections were stained and examined as described for Regular EM.

Statistical analysis {#s24}
--------------------

Data were analyzed using either Student's two-tailed unpaired *t* test or one-way analysis of variance followed by Dunnett's post-hoc tests (Graphpad Prism 7.0 Software). Differences were considered statistically significant when P \< 0.05. For slice cultures used for preparation of insoluble fractions and immunoblotting, three wells containing three slice cultures each (nine total) were pooled together, and *n* refers to each group of pooled slices. For immunohistochemistry and Thioflavin S staining, *n* refers to each individual slice. For EthD-1 uptake assays, *n* refers to each individual slice, which was imaged three times and positive cell numbers averaged across the three images.

Online supplemental material {#s25}
----------------------------

Fig. S1 shows the inefficient transduction by rAAV2/5 and 2/7. Fig. S2 shows transduction of multiple CNS cell types in the same BSC and counterstaining of cell markers to show cell-specific transduction in BSCs. Fig. S3 shows long-term expression of rAAVs in neurons and astrocytes. Fig. S4 shows an absence of Thioflavin S inclusions by 28 DIV with transduction of WT, S320F, P301L, or P301S tau.
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